Pirtobrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Approved
Selectivity scorecard
KISS
99.49
Gini
0.656
CATDS
0.024
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Pirtobrutinib. Strongest target: BTK at 97.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | BTK | 97.7% | 2.3% |
| 2 | ERBB4_HER4 | 95.7% | 4.3% |
| 3 | MEK2 | 89.3% | 10.7% |
| 4 | BRK | 88.1% | 11.9% |
| 5 | YES_YES1 | 82.6% | 17.4% |
| 6 | MEK1 | 81.8% | 18.2% |
| 7 | C_KIT | 69.7% | 30.3% |
| 8 | TEC | 66.9% | 33.1% |
| 9 | TXK | 65.1% | 34.9% |
| 10 | JAK2 | 63.3% | 36.7% |
| 11 | TNIK | 59.5% | 40.5% |
| 12 | LCK | 58.3% | 41.7% |
| 13 | FYN | 58.1% | 41.9% |
| 14 | CSK | 56.0% | 44.0% |
| 15 | FGR | 53.3% | 46.7% |
| 16 | FGFR1 | 52.0% | 48.0% |
| 17 | IRAK1 | 50.1% | 49.9% |
| 18 | AURORA_C | 49.7% | 50.3% |
| 19 | FGFR2 | 48.9% | 51.1% |
| 20 | FMS | 47.3% | 52.7% |
Selectivity landscape
Where Pirtobrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Pirtobrutinib.
Atlas insights for Pirtobrutinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target4%
Off-target96%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1499.00 | |
| ALLOGRAFT_REJECTION | 5638.93 | |
| ANDROGEN_RESPONSE | 1131.76 | |
| ANGIOGENESIS | 948.79 | |
| APICAL_JUNCTION | 5305.97 | |
| APICAL_SURFACE | 684.99 | |
| APOPTOSIS | 4062.08 | |
| BILE_ACID_METABOLISM | 576.30 | |
| CHOLESTEROL_HOMEOSTASIS | 694.37 | |
| COAGULATION | 597.50 | |
| COMPLEMENT | 3051.13 | |
| DNA_REPAIR | 1230.87 | |
| E2F_TARGETS | 2809.50 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1187.97 | |
| ESTROGEN_RESPONSE_EARLY | 1699.80 | |
| ESTROGEN_RESPONSE_LATE | 1727.84 | |
| FATTY_ACID_METABOLISM | 572.20 | |
| G2M_CHECKPOINT | 2969.57 | |
| GLYCOLYSIS | 1478.48 | |
| HEDGEHOG_SIGNALING | 527.13 | |
| HEME_METABOLISM | 1280.72 | |
| HYPOXIA | 2534.27 | |
| IL2_STAT5_SIGNALING | 2047.55 | |
| IL6_JAK_STAT3_SIGNALING | 3221.94 | |
| INFLAMMATORY_RESPONSE | 2982.57 | |
| INTERFERON_ALPHA_RESPONSE | 591.77 | |
| INTERFERON_GAMMA_RESPONSE | 3753.95 | |
| KRAS_SIGNALING_DN | 542.64 | |
| KRAS_SIGNALING_UP | 1952.86 | |
| MITOTIC_SPINDLE | 3758.14 | |
| MTORC1_SIGNALING | 2454.79 | |
| MYC_TARGETS_V1 | 1804.46 | |
| MYC_TARGETS_V2 | 387.51 | |
| MYOGENESIS | 1933.69 | |
| NOTCH_SIGNALING | 192.51 | |
| OXIDATIVE_PHOSPHORYLATION | 993.76 | |
| P53_PATHWAY | 2212.32 | |
| PANCREAS_BETA_CELLS | 206.38 | |
| PEROXISOME | 598.14 | |
| PI3K_AKT_MTOR_SIGNALING | 5497.20 | |
| PROTEIN_SECRETION | 1292.80 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 303.21 | |
| SPERMATOGENESIS | 842.18 | |
| TGF_BETA_SIGNALING | 1078.63 | |
| TNFA_SIGNALING_VIA_NFKB | 2678.02 | |
| UNFOLDED_PROTEIN_RESPONSE | 764.88 | |
| UV_RESPONSE_DN | 2748.19 | |
| UV_RESPONSE_UP | 2106.49 | |
| WNT_BETA_CATENIN_SIGNALING | 1188.16 | |
| XENOBIOTIC_METABOLISM | 1273.75 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.845 |
| SRR23303752 | — | 0.837 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.830 |
| SRR10899984 | — | 0.828 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.826 |
Annotations
Sign in to read and post annotations.
Loading…